| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
|
Thunnissen, E.
|
|
|
138 |
C |
p. 13-18
|
artikel
|
| 2 |
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
|
Hida, Toyoaki
|
|
|
138 |
C |
p. 124-130
|
artikel
|
| 3 |
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)
|
Asahina, Hajime
|
|
|
138 |
C |
p. 65-71
|
artikel
|
| 4 |
Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer
|
Park, Seong Yong
|
|
|
138 |
C |
p. 1-5
|
artikel
|
| 5 |
Contents
|
|
|
|
138 |
C |
p. v-vi
|
artikel
|
| 6 |
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
|
She, Longjiang
|
|
|
138 |
C |
p. 88-94
|
artikel
|
| 7 |
Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors
|
Puliti, Donella
|
|
|
138 |
C |
p. 72-78
|
artikel
|
| 8 |
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
|
Hermans, B.C.M.
|
|
|
138 |
C |
p. 102-108
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
138 |
C |
p. iii
|
artikel
|
| 10 |
Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy
|
Shen, Chia-I
|
|
|
138 |
C |
p. 52-57
|
artikel
|
| 11 |
Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” [Lung Cancer, 108 (June 2017) 228–231]
|
Ou, Sai-Hong Ignatius
|
|
|
138 |
C |
p. 141
|
artikel
|
| 12 |
Erratum to “Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer” [Lung Cancer 132 (June) (2019) 154–156]
|
Lan, Shaowei
|
|
|
138 |
C |
p. 142
|
artikel
|
| 13 |
Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy
|
Ikematsu, Yuki
|
|
|
138 |
C |
p. 58-64
|
artikel
|
| 14 |
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options
|
Jurmeister, Philipp
|
|
|
138 |
C |
p. 43-51
|
artikel
|
| 15 |
Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden
|
Naito, Tomoyuki
|
|
|
138 |
C |
p. 35-42
|
artikel
|
| 16 |
Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study
|
Buikhuisen, W.A.
|
|
|
138 |
C |
p. 139-140
|
artikel
|
| 17 |
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
|
Pérol, Maurice
|
|
|
138 |
C |
p. 79-87
|
artikel
|
| 18 |
Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system)
|
Stamatis, Georgios
|
|
|
138 |
C |
p. 19-26
|
artikel
|
| 19 |
Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience
|
Chiappetta, Marco
|
|
|
138 |
C |
p. 27-34
|
artikel
|
| 20 |
Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis
|
Eichhorn, F.
|
|
|
138 |
C |
p. 95-101
|
artikel
|
| 21 |
Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer
|
Ager, Bryan J.
|
|
|
138 |
C |
p. 6-12
|
artikel
|
| 22 |
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
|
Subramanian, Janakiraman
|
|
|
138 |
C |
p. 131-138
|
artikel
|
| 23 |
Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease
|
Zhou, Na
|
|
|
138 |
C |
p. 116-123
|
artikel
|
| 24 |
Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer
|
Bar, Jair
|
|
|
138 |
C |
p. 109-115
|
artikel
|
Tijdschrift beschrijving